New drug Y-3 passes first safety check in small human study
NCT ID NCT06770491
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 20 times
Summary
This early-stage study tested the safety and how the body handles a new drug called Y-3 in 20 healthy adults. Participants received a single dose of 40 mg, 60 mg, or a placebo. The goal was to measure drug levels in the blood and check for any side effects, not to treat a disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOLERABILITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tranquil Clinical Research
Webster, Texas, 77598, United States
Conditions
Explore the condition pages connected to this study.